Results 91 to 100 of about 44,308 (198)

Treatment of Older Patients with Mantle-Cell Lymphoma [PDF]

, 2012
BACKGROUND: The long-term prognosis for older patients with mantle-cell lymphoma is poor. Chemoimmunotherapy results in low rates of complete remission, and most patients have a relapse.
B. Coiffier, C. Thieblemont, C.H. Geisler, Cheson BD, E. Hoster, F. Di Raimondo, Foran JM, G. Lepeu, H. Tilly, H.C. Kluin-Nelemans, J. Walewski, J.K. Doorduijn, J.M. Zijlstra, L. Kanz, L. Sanhes, M. André, M. Hallek, M. Macro, M. Pfreundschuh, M. Szymczyk, M. Trneny, M. Unterhalt, M. Uppenkamp, M.H. Dreyling, O. Hermine, P. Feugier, P.J. Lugtenburg, R. Bouabdallah, R. Forstpointner, S. Kremers, S. Stilgenbauer, U. Vehling-Kaiser, Unterhalt M, V. Procházka, V. Ribrag, W. Hiddemann, W. Klapper, Zinzani PL   +37 more
core   +2 more sources

Diffuse Large B‐Cell Lymphoma of the Thyroid in a Patient With Hashimoto Thyroiditis: A Diagnostic Dilemma

Clinical Case Reports, Volume 13, Issue 11, November 2025.
ABSTRACT Primary thyroid lymphoma (PTL) is a rare malignancy, comprising 1%–5% of thyroid cancers and 2%–5% of extranodal lymphomas, with diffuse large B‐cell lymphoma (DLBCL) being the most common subtype. PTL often coexists with Hashimoto thyroiditis, leading to diagnostic delays.
Shravya Singh Karki, Shivam Pandey, Smriti Karki, Deepak Paudel, Chahana Pathak   +4 more
wiley   +1 more source

Spontaneous Splenic Rupture and Rituximab-Induced Acute Thrombocytopenia in a Patient with High-Risk Mantle Cell Lymphoma

Case Reports in Hematology, 2019
Mantle cell lymphoma is a relatively rare type of mature B-cell non-Hodgkin’s lymphoma with an incidence of approximately 8 cases per million persons per year.
Jared Williams, Shingi Chiruka
doaj   +1 more source

Vitamin D3 receptor is highly expressed in Hodgkin's lymphoma [PDF]

, 2012
Background: Hodkin s lymphoma is one of the most frequent lymphoma in western world. Despite an overall good prognosis some patients suffer relapsing tumors which are difficult to cure.
Benz, Alexander, Christoph, Renné, Hansmann, Martin L.   +2 more
core   +2 more sources

Polatuzumab vedotin and CD79B: A study of efficacy in R‐CHOP‐resistant diffuse large B‐cell lymphoma

British Journal of Haematology, EarlyView.
Nicolas Munz, Alberto J. Arribas, Roberta Bordone Pittau, Federico Simonetta, Georg Stussi, Francesco Bertoni   +5 more
wiley   +1 more source

Routine Monitoring of CAR‐T‐Cells Expansion and Persistence in Patients With Aggressive Large B‐Cell Lymphoma by Flow Cytometry: A Single‐Center Experience

Hematological Oncology, Volume 43, Issue 6, November 2025.
ABSTRACT This retrospective, single‐center study evaluated routine flow cytometry (FC) monitoring of CAR‐T‐cells in 45 patients with aggressive large B‐cell lymphoma (LBCL). CAR‐T‐cells expansion was assessed from Day 0 to Month 12. Peak expansion occurred on Day 7 after axi‐cel (median 39.3% of total lymphocytes; 87 cells/mm3) and Day 10 for tisa‐cel (
Alexandra Zduniak, Jérémie Martinet, Emilie Lévêque, Stéphanie Becker, David Tonnelet, Elodie Dos Santos, Claire Leroy, Mustafa Alani, Jean Rouvet, Marine Brousseau, Camille Giverne, Alexis Cuffel, Serge Jacquot, Arnaud Roucheux, Alice Veuiller, Nicolas Lecornu, Misa Eugene Norbert, Olivier Boyer, Hervé Tilly, Fabrice Jardin, Jean‐Baptiste Latouche, Vincent Camus   +21 more
wiley   +1 more source

Impact of novel therapies for mantle cell lymphoma in the real world setting : a report from the UK's Haematological Malignancy Research Network (HMRN) [PDF]

, 2018
The treatment landscape for mantle cell lymphoma (MCL) has changed dramatically in recent years, with findings from clinical trials reporting improvements in survival. Data on the general patient population are, however, sparse; and it is unclear whether
Abrahamsson, Abrahamsson, Andersen, Atilla, Chandran, Colbourn, Dreyling, Dreyling, Dreyling, Epperla, Furtado, Gouill, Harris, Herrmann, Hill, Hoster, Hoster, Kahl, Klapper, Kluin-Nelemans, Kuittinen, Kurnaz, Leonard, Leux, Marcos-Gragera, Martin, Martin, Martin, McKay, Rule, Rule, Rummel, Rummel, Sawalha, Schulz, Smith, Smith, Swerdlow, Vergote, Vidal, Wang, Zaja   +41 more
core   +1 more source

Machine Learning for Prediction of High‐Risk Hospitalizations in Lymphoma Patients: A Danish Population‐Based Study

European Journal of Haematology, Volume 115, Issue 5, Page 443-453, November 2025.
ABSTRACT Objective Infections are a leading cause of hospitalization in patients treated for lymphoma and can be life‐threatening. This study developed a machine learning (ML)‐based risk stratification method to classify infection‐related hospitalizations (IRH) into serious‐IRH (S‐IRH) and non‐serious‐IRH (NS‐IRH).
Alexander Djupnes Fuglkjaer, Deniz Kenan Kilic, Mathias Holmsgaard Eskesen, Mikkel Runason Simonsen, Laurids Østergaard Poulsen, Carsten Utoft Niemann, Paw Jensen, Kirstine Kobberøe Søgaard, Mikkel Werling, Frederik Christensen, Izabela Ewa Nielsen, Tarec Christoffer El‐Galaly   +11 more
wiley   +1 more source

A phase I/II study of 10-min dosing of bendamustine hydrochloride (rapid infusion formulation) in patients with previously untreated indolent B-cell non-Hodgkin lymphoma, mantle cell lymphoma, or relapsed/refractory diffuse large B-cell lymphoma in Japan. [PDF]

Cancer Chemother Pharmacol, 2022
Ishizawa K, Yokoyama M, Kato H, Yamamoto K, Makita M, Ando K, Ueda Y, Tachikawa Y, Suehiro Y, Kurosawa M, Kameoka Y, Nagai H, Uoshima N, Ishikawa T, Hidaka M, Ito Y, Utsunomiya A, Fukushima K, Ogura M.   +18 more
europepmc   +1 more source

Non-Hodgkin and Hodgkin Lymphomas Select for Overexpression of BCLW. [PDF]

, 2017
Purpose: B-cell lymphomas must acquire resistance to apoptosis during their development. We recently discovered BCLW, an antiapoptotic BCL2 family member thought only to contribute to spermatogenesis, was overexpressed in diffuse large B-cell lymphoma ...
Adams, Clare M., Eischen, Christine M., Gong, MD, Jerald Z., Mitra, Ramkrishna   +3 more
core   +1 more source